Caprock Group LLC Takes $623,000 Position in Edwards Lifesciences Co. (NYSE:EW)

Caprock Group LLC bought a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, according to its most recent filing with the SEC. The fund bought 8,411 shares of the medical research company’s stock, valued at approximately $623,000.

Other institutional investors have also made changes to their positions in the company. FSA Wealth Management LLC bought a new position in Edwards Lifesciences during the 3rd quarter valued at about $30,000. Prospera Private Wealth LLC bought a new position in Edwards Lifesciences during the 3rd quarter valued at about $32,000. Avior Wealth Management LLC lifted its holdings in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the last quarter. JFS Wealth Advisors LLC lifted its holdings in Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 166 shares during the last quarter. Finally, Roble Belko & Company Inc bought a new position in Edwards Lifesciences during the 4th quarter valued at about $46,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Down 0.1 %

Edwards Lifesciences stock opened at $71.33 on Wednesday. The stock has a market capitalization of $42.07 billion, a PE ratio of 10.29, a price-to-earnings-growth ratio of 3.72 and a beta of 1.11. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a 50 day moving average of $72.49 and a 200-day moving average of $69.63.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 8,000 shares of company stock worth $547,430. 1.27% of the stock is owned by insiders.

Analysts Set New Price Targets

EW has been the subject of several analyst reports. Robert W. Baird cut their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. The Goldman Sachs Group boosted their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Wolfe Research downgraded shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 target price for the company. in a research note on Thursday, January 16th. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $79.19.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.